• 07 Mar 2024
• Admin
• News Article

Fibrocor Therapeutics Collaborates with MSRD

Fibrocor Therapeutics inks R&D collaboration with MSRD to advance Alport Syndrome programme

Overview 

Fibrocor Therapeutics Inc., a privately held developer of novel therapeutics to treat fibrosis, announces that it has entered into a research and development collaboration with the McQuade Center for Strategic Research and Development, LLC (MSRD) to advance its Alport Syndrome programme. The agreement includes a single digit million US$ upfront payment and additional funding that has the potential to cover the cost of studies through phase 1b. MSRD, a member of the Otsuka family of pharmaceutical companies, identifies and supports early-stage opportunities that can change the landscape of treatments for mental illness and renal disorders.

About FIB918

1. FIB918 is now in the IND-enabling phase and phase 1 clinical trials of the monoclonal antibody are targeted to start in late 2025. 
2. Fibrocor and MSRD will be working with patients, advocacy groups and regulators to execute safe, effective and inclusive clinical trials that take patient input and lifestyle into consideration, aiming to positively shift the clinical and treatment paradigm for patients.

Word from CEO: Fibrocor

• William P. Newsome III, CEO, president of Fibrocor said: “This collaboration with the experienced team at MSRD, coupled with research funding, represents continued validation of Fibrocor’s translational, best-in-class, target discovery platform. 
• It represents hope and potential for individuals grappling with Alport Syndrome worldwide. FIB918 has the potential to deliver a significant advancement in the treatment of patients afflicted by this debilitating disease, where current options are limited. 
• The completion of our Investigational New Drug (IND) application and the anticipated commencement of clinical trials in 2025, mark crucial milestones in our journey to make a meaningful impact on the lives of those affected by Alport Syndrome.”

Fibrocor Scientific Advisor on Their Commitment

• Piet Wigerinck, chief scientific advisor of Fibrocor added, “This collaboration serves as further affirmation of our platform, aligning committed teams that are backed by world class experts and substantial resources. 
• It propels our ongoing commitment to advancing our small molecule programme, with FIB992 poised for entry into the clinic later this year for idiopathic pulmonary fibrosis (IPF), another debilitating, deadly and underserved fibrotic disease. 
• This will be followed by the initiation of clinical trials for FIB991 for chronic allograft nephropathy in 2025. We have an unwavering dedication to making a meaningful impact on patients grappling with fibrotic diseases. We eagerly anticipate a successful collaboration with our colleagues at MSRD.”

About Alport Syndrome

• Alport Syndrome is a rare form of kidney inflammation caused by specific gene mutations, resulting in structural defects and the development of renal fibrosis and kidney failure. 
• About one in 50,000 people is thought to suffer from it, although estimates vary widely. 
• Most experience kidney failure as young adults or by middle age.

Idiopathic Pulmonary Fibrosis

• Idiopathic pulmonary fibrosis (IPF) is a progressive and generally fatal disease characterized by scarring of the lungs that thickens the lining of the lungs, causing an irreversible loss of the tissue’s ability to transport oxygen. 
• IPF ultimately robs a patient of the ability to breathe. 
• The median survival of IPF patients is reported to range from two to five years.

About Fibrocor

Fibrocor Therapeutics is redefining the landscape of fibrotic diseases through our unique portfolio of novel compounds against biologically and clinically validated targets.